A carregar...
ABCB1 Overexpression Is a Key Initiator of Resistance to Tyrosine Kinase Inhibitors in CML Cell Lines
The tyrosine kinase inhibitor (TKI) imatinib has resulted in excellent responses in the majority of Chronic Myeloid Leukaemia (CML) patients; however, resistance is observed in 20–30% of patients. More recently, resistance to the second generation TKIs, nilotinib and dasatinib, has also been observe...
Na minha lista:
| Publicado no: | PLoS One |
|---|---|
| Main Authors: | , , |
| Formato: | Artigo |
| Idioma: | Inglês |
| Publicado em: |
Public Library of Science
2016
|
| Assuntos: | |
| Acesso em linha: | https://ncbi.nlm.nih.gov/pmc/articles/PMC4990177/ https://ncbi.nlm.nih.gov/pubmed/27536777 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1371/journal.pone.0161470 |
| Tags: |
Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!
|